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The protein folding machinery of the endoplasmic reticulum (ER) ensures
that proteins entering the eukaryotic secretory pathway acquire appropriate
post-translational modifications and reach a stably folded state. An impor-
tant component of this protein folding process is the supply of disulfide
bonds. These are introduced into client proteins by ER resident oxidoreduc-
tases, including ER oxidoreductin 1 (Ero1). Ero1 is usually considered to
function in a linear pathway, by ‘donating’ a disulfide bond to protein dis-
ulfide isomerase (PDI) and receiving electrons that are passed on to the
terminal electron acceptor molecular oxygen. PDI engages with a range of
clients as the direct catalyst of disulfide bond formation, isomerization or
reduction. In this paper, we will consider the interactions of Ero1 with
PDI family proteins and chaperones, highlighting the effect that redox flux
has on Ero1 partnerships. In addition, we will discuss whether higher
order protein complexes play a role in Ero1 function.1. Oxidative protein folding in the endoplasmic reticulum
Disulfide bonds are formed between two cysteine residues, either within
proteins (intramolecular disulfides) or between proteins (intermolecular disul-
fides) [1]. This is a rare occurrence in the cell cytosol because the reducing
environment favours free thiols (–SH). However, in the bacterial periplasm
[2], the mitochondrial intermembrane space and the eukaryotic endoplasmic
reticulum (ER [3]), the environment is more oxidizing and favours disulfide
bond formation (S–S). In the ER, native disulfide bonds are integrated into pro-
teins early during the folding process [4]. This occurs while the protein is being
threaded through the translocon during, or shortly after, translation. The pro-
cess of ensuring that a protein is properly folded and equipped with the
correct disulfide bond arrangements is carefully coordinated by various protein
disulfide isomerases (PDIs), oxidoreductases, chaperones and other folding
factors [5]. These folding assistants ensure that disulfide bond formation is
coupled to other post-translational modifications, such as the introduction of
N-linked glycans and to quality control processes [6]. The main players
involved in oxidative folding and quality control have been identified, but
how they interact and work together in a coordinated fashion is not fully under-
stood. The ER can be viewed as the control point for a cell’s secretory output
and for the integrity of proteins within the secretory pathway itself. Thus,
understanding how the ER machinery works in different cells and tissues is
essential for us to tackle various biological problems, ranging from diseases
of misfolding to the need for improved production of recombinant proteins.
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Figure 1. The redox state and interactions of Ero1a are cell-type dependent.
(a) Equal amounts of lysates from HT1080 cells (lanes 1 and 4), HeLa cells (lanes
2 and 5) and THP1 cells (lanes 3 and 6) were analysed by non-reducing (lanes
1–3) or reducing (lanes 4–6) SDS-PAGE and probed for Ero1a expression.
Endogenous disulfide-bonded complexes with PDI (asterisk) and other proteins
(double asterisk) can be detected at steady state. Molecular weight markers of
50, 100 and 150 kDa are shown as dots. (b) A schematic of the disulfide bonds
(black lines) of Ero1p, Ero1a (Ox2) and Ero1b (Ox). In Ero1a Ox2, the C94–
C131 disulfide precludes formation of a disulfide at the active site C94–C99
(shown in bold). An analogous regulatory disulfide between C90 and C130 is
found in Ero1b together with a likely additional long-range disulfide between
C100 and C262 (hatched line). Note that the regulatory cysteines differ between
Ero1a/b and Ero1p. The most N-terminal cysteine residues are not shown for
simplicity. Disulfide bond flow from the C-terminal active site cysteines to the
N-terminal active site cysteines (shown in bold) is depicted by a grey arrow.
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Two of the major contributors to disulfide bond formation in
the ER are PDI and the ER oxidoreductin (or oxidoreductase)
Ero1. There is a solitary Ero1 protein in Saccharomyces cerevisiae
(Ero1p [7,8]) and two (Ero1a and Ero1b [9,10]) in mammals.
Together, PDI and Ero1 proteins harness the oxidizing power
of molecular oxygen to create de novo disulfide bonds in
a newly folding protein [11,12]. The exchange of disulfide
bonds from Ero1 to PDI to client necessitates electron flow in
the reverse direction, from client to PDI to Ero1. Ero1s use the
cofactor flavin adenine dinucleotide (FAD) to reduce molecular
oxygen, generating peroxide in the process [13,14]. PDI is able
to supply, rearrange (isomerize) or reduce disulfide bonds in
a client protein [15]. The ability of PDI to perform these func-
tions depends on its two redox-active a and a0 thioredoxin
domains [16]. The a type domains are separated by two
redox-inactive b domains in an abb0xa0 arrangement [17,18],
where the x linker region contributes tomobility andmodulates
client access to PDI [19,20]. The PDI a type domains have
CGHC active sites: their high biochemical reduction potential
(2180 mV) makes PDI thermodynamically suited for donating
disulfide bonds to reduced protein clients [21]. During disulfide
bond formation inmammalian cells, the a domain of PDI is oxi-
dized by its a0 domain [22] after the a0 domain of PDI has been
preferentially oxidized by Ero1a [23,24]. The C94xxxxC99 region
(x¼ any amino acid), on a flexible loop of Ero1a, effects the
transfer of disulfide bonds from Ero1a to the a0 domain of
PDI [25]. In turn, the C94xxxxC99 site of Ero1a receives a disul-
fide bond from the C394xxC397 site, which is in direct
communication with the FAD moiety [26]. A similar mechan-
ism occurs in S. cerevisiae [27]; however, in yeast, Pdi1p is
glycosylated, and in the context of the full-length protein, the
a domain functions better as an isomerase, with the a0
domain being a better oxidase [28].
Although Ero1p is essential for yeast (and Caenorhabditis
elegans) viability, mice deficient in both Ero1a and Ero1b are
viable [29], which stimulated the search for supplementary
pathways of disulfide bond formation in the ER (reviewed in
[30,31]). Alongside Ero1, additional sources of disulfide bond
equivalents to PDI include peroxiredoxin IV [32,33], gluta-
thione peroxidases [34] and vitamin K epoxide reductase [35].
The sulfhydryl oxidase QSOX can oxidize some substrates of
the secretory pathway and extracellular matrix directly [36]
and the selenoprotein Sep15 may also contribute to disulfide
bond reduction/isomerization during glycoprotein quality
control [37]. Low molecular weight thiols, principally
glutathione, also regulate the redox balance of the ER [38,39].3. The regulatory poise of Ero1a differs
between cell types
Although the general flow of disulfides between Ero1 and PDI
is now understood, many key points remain unknown. In
higher eukaryotes, there are over 20 PDI homologues.
Although some of them lack redox-active a-type domains,
the majority are likely to be directly involved in disulfide
bond formation or regulation [15,40]. In yeast, there is a
hierarchy of interactions between Ero1p and the Pdi1p homol-
ogues [41], but it is not clear how many PDIs require Ero1 for
the provision of disulfide bond equivalents in mammalian
cells. Mammalian disulfide bond formation may also beregulated differently in diverse tissue types or physiological
settings. To illustrate this, figure 1 shows an experiment
inwhich the expression of Ero1awas analysed byWestern blot-
ting at steady state in three different cell lines, HT1080 (a
fibrosarcoma), HeLa (a cervical carcinoma) and THP1
(a monocytic leukaemia). The proteins in the cell lysates were
separated electrophoretically under non-reducing conditions
(figure 1a, lanes 1–3), which allow disulfide-dependent inter-
actions to be preserved, and reducing conditions, which
instead disrupt disulfide bonds (figure 1a, lanes 4–6). It is
known from previously published experiments that under
non-reducing conditions, monomeric Ero1a can exist as a
reduced form (R) and two partially oxidized forms, Ox1 and
Ox2 [42]. TheOx2 formhas a regulatory disulfide bondbetween
C94 andC131 that inactivates the redox activityof Ero1a [23,43].
Endogenous Ero1a in HT1080 and HeLa cells was almost
exclusively found in the compact Ox2 form (figure 1a, lanes 1
and 2) and represents an inactive reservoir of the protein. By
contrast, THP1 cells expressed more of the active Ox1 form of
Ero1a (figure 1a, lane 3). The fully reduced form of Ero1a
was not detectable in either cell line at steady state by the
2G4 antibody. These cell lines do have a high secretory
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balance? One possibility is that Ero1a is involved in a wider
range of biological processes in monocytes and macrophages,
which are professional antigen-presenting cells of the
immune system. In support of this idea, it has been shown
that Ero1a regulates the ER calcium channel IP3R and
hence indirectly controls the release of calcium from the ER
[44], a process that can induce apoptosis [45]. Ero1a localizes
tomitochondrial-associatedmembranes (MAMs) under oxidiz-
ing conditions, where transfer of calcium can occur [44,46,47]
and calcium sensing studies using fluorescent probes suggest
that calcium levels respond to changes in Ero1a activity [48].
In cultured macrophages, Ero1a can subsequently induce the
activation of the NADPH oxidase complex [49], which gener-
ates superoxide for the destruction of ingested pathogenic
bacteria and mycobacteria. NADPH oxidase 2 function is
important because genetic defects in components of the com-
plex can lead to X-linked chronic granulomatous disease,
which results in life-threatening bacterial infections [50]. It
will be interesting to test whether NADPH oxidase activity
can be controlled by modulating the Ero1a oxidation state,
and to assess the relative contribution of Ero1a to calcium sig-
nalling compared with oxidative protein folding. Thus, it is
becoming apparent that Ero1a function is not strictly limited
to oxidative protein folding, but can contribute to multiple bio-
chemical pathways, including cross-compartmental calcium
fluxes and redox communication.4. Ero1a engages in multiple disulfide-
dependent interactions
Another possible explanation for cell-specific differences in
Ero1a oxidation state is that Ero1a could be regulated by
different PDI family members, such as ERp44, ERp57 and
ERp72 [51–54], and these proteins may vary in their ability
to reduce Ero1 regulatory disulfide bonds. In support of
this idea, the experiment shown in figure 1a illustrates that
Ero1a can be trapped in inter-molecular, disulfide-dependent
complexes with different partners that vary depending on the
cell type. Whereas Ero1a interacted equally well with a
protein that is likely to be PDI (figure 1a, asterisk) in all
three cell lines, additional inter-molecular Ero1a interactions
can be seen in THP1 cells (figure 1a, lane 3, double asterisk).
These interacting proteins have yet to be formally identified,
but based on published and unpublished data, one is likely to
be the PDI homologue ERp44, which was identified as a
novel protein important for ER retention of Ero1a by the
Sitia group [51]. ERp44 was subsequently shown to be
involved in the quality control of the IgM immunoglobulin
[55], adiponectin [56] and the serotonin receptor SERT [57].
These studies suggest that ERp44 is important for the assem-
bly of proteins into oligomers, and probably acts as a
platform upon which its clients are assembled prior to deliv-
ery to ER exit sites and post-ER compartments such as the
ERGIC [58,59]. ERp44 is also important for the regulation
of IP3R1 [60], which is of particular interest given the link
between Ero1a and IP3R1 in macrophages discussed in the
previous section. ERp44 mutants that bind Ero1a at high affi-
nity inhibit oxygen consumption [25], but further work is
required to determine how ERp44 directly regulates the oxi-
dation state, and hence activity, of Ero1a in different cell
types. However, experiments in transfected HeLa cells haveshown that the interaction between ERp44 and Ero1a is inde-
pendent of a hydrophobic hairpin in Ero1a that is required
for full binding of Ero1a to PDI. PDI and ERp44, therefore,
interact with Ero1a differently, providing scope for fine-
tuning the activity of Ero1a in different cells and tissues [25].5. Redox-sensitive regulation of Ero1a
Elegant studies with yeast Ero1p [61–63], mammalian Ero1a
[23,24,43,64] and mammalian Ero1b [65] have mapped out
the regulatory disulfide bonds that control the activity of
Ero1 proteins. These regulatory disulfides and their relation-
ship to the redox-active cysteines are outlined in figure 1b.
The C94–C131 regulatory disulfide bond in Ero1a ‘locks
down’ residue C94; this prevents the active site C94–C99 dis-
ulfide from forming and subsequently donating a disulfide to
PDI. The robustness of this intrinsic control system and its very
rapid responsiveness to fluctuations in the redox environment
is highlighted by three previously unpublished experiments
from our laboratories (figures 2–4). HeLa cells transfected
with Ero1a were exposed to various concentrations of the
reducing agent dithiothreitol (DTT) in culture, radiolabelled
and the DTT quenched with excess N-ethylmaleimide (NEM;
figure 2). Analysis of the cell lysates by immunoprecipitation
and non-reducing sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS–PAGE) showed that the inactive oxi-
dized Ox2 form of Ero1a was readily reduced when 1.25 mM
DTT was added to the cell, whereas the partially oxidized
(active) Ox1 form could resist reduction, with up to at least
20 mMDTT. Interestingly, a number of additional Ero1a disul-
fide-dependent complexes were revealed upon addition of
1.25 mM DTT (figure 2a, lane 2). These complexes may rep-
resent oligomers that reside in higher molecular-weight
complexes during oxidizing conditions. The Ero1a associated
proteins may be additional regulatory or accessory proteins
(such as chaperones or PDI family members) that are recruited
to Ox1 or to partially reduced Ero1a during the oxidation
cycle. The bands in the 75–150 kDa region of the gel are
likely to represent specific disulfide-dependent protein inter-
actions with Ero1a because they are reduced by adding DTT
to the sample buffer prior to SDS-PAGE (figure 2b).
As the DTT concentration applied to the living cell
was increased, the intensity of the Ox2 signal declined (figure
2a, lanes 1–2), as did the total Ero1a signal (figure 2b, lanes
1–2). Because the signal of PDI (immunoprecipitated from the
same lysates) remained similar between 0 and 1.25 mM DTT
(figure 2c, lanes 1–2), the loss of signal was Ero1a specific.
The loss of signal could reflect impaired detergent solubility
in Triton X-100 owing to aggregation, loss of protein owing to
degradation by ER quality control mechanisms or loss of anti-
body reactivity after post-translational modification. However,
given the fact that the polyclonal antiserum recognizes a
range of conformations and redox states of Ero1a, we favour
the former explanation. Given the relationship between Ero1a
and calcium signalling described above, it would be intriguing
to determine whether the changes in Ero1a signal intensity
relate to its recruitment to MAMs or to ER detergent-resistant
membranes in a redox-dependent manner.
The DTT-induced change from Ox2 to Ox1 can be
explained structurally by the transition of Ero1a from a com-
pact form with an intact regulatory C94–C131 disulfide (Ox2)
to a more ‘open’ active form (Ox1) in which the regulatory
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Figure 2. Selective reduction of Ero1a complexes. HeLa cells transfected with Ero1a were metabolically labelled for 5 min in the presence of 0, 1.25, 2.5, 5, 10 or
20 mM DTT and post-nuclear lysates subjected to immunoprecipitation using antibody D5. Samples were analysed on (a) non-reducing or (b) reducing 7.5% SDS-
PAGE. The 120 kDa complex is indicated by an asterisk and molecular weight markers of 50, 75, 100 and 150 kDa are shown as dots. Alternatively, aPDI was used to
retrieve PDI from the same lysates prior to analysis on reducing 7.5% SDS-PAGE (c). Ero1a R, Ox1 and Ox2 are indicated by greater than symbol (.). (d ) Cartoon to
illustrate the active ‘open’ form of Ero1a Ox1 compared with the more compact Ero1a Ox2. Ox1 lacks the regulatory C94–C131 disulfide and recruits reduced PDI
for re-oxidation. For simplicity, only C94–C99 is shown. The higher apparent molecular weight of Ero1a in (b) lane 1 could be due to increased binding of
NEM to more free cysteines, a change in the accessibility of a cysteine residue(s) to NEM or an alternative, redox-dependent post-translational modification at
a cysteine residue.
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C94–C99 disulfide is consequently primed to donate a
disulfide to reduced PDI, which lacks regulatory disulfides.6. Dithiothreitol-induced structural changes in
Ero1a are reversible
To respond to changes in the redox environment, Ero1amust
switch rapidly between active and inactive states. To assess
how rapidly Ero1a altered its equilibrium when exposed to
a redox shift, we investigated how the protein responded
when oxidizing conditions were restored after a 5 min chal-
lenge with 5 mM DTT (figure 3). Ero1a partitions into R
and active Ox1 during the 5 min pulse, with the Ero1a-PDI
complex maintained under these conditions (figure 3a,
lane 1). From previously published work, the Ero1a–PDI
complex is likely to comprise both mature and radiolabelled
PDI and Ero1a [42]. When DTT was washed out, the normal
oxidation pattern of Ero1a was restored within 10 mins. The
diffuse 120 kDa complex (*) and higher molecular weightcomplexes reformed within 3 min (figure 3a, lane 2).
Re-oxidation of Ero1a resulted in rapid recovery of the inac-
tive Ox2 form demonstrating that Ero1a is responsive to
changes in the ER redox state.
Observation of the reducing gel showed an increase in the
total Ero1a signal retrieved when cells were shifted from
reducing to oxidizing conditions (figure 3a, lanes 5 and 6).
Consistent with this experiment, the opposite pattern was
seen when cells were shifted from oxidizing to reducing con-
ditions (figure 2b, lanes 1 and 2). This observation shows that
the decrease in signal in figure 2b cannot be explained by
degradation of Ero1a. Ero1a became more accessible to
NEM when the reducing agent was removed and the
environment was made more oxidizing (compare figure 3a,
lanes 5 and 6 with figure 2b, lanes 1–2), consistent with the
finding that Ero1b FAD-binding site mutants make cysteines
available in a temperature- or stress-dependent manner [66].
This somewhat counterintuitive finding is illustrated schema-
tically in figure 3b. When Ero1a is covalently modified by
NEM, it gains molecular weight and hence runs more
slowly (higher up) in a reducing gel. Ero1a in the Ox2 form
1 2 3 4 5 6 7 8
aEro1a(a)
(b)
non-reducing
0
*
R      >
Ox1 >
Ox2 >
3 6 10 0 3 6
aEro1a
reducing
NEM NEMEro1a
Ero1a
Ox2
NEM
Ox1
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NEM X
Mr
∑ 150
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Figure 3. Post-translational oxidation of Ero1a. (a) HeLa cells transfected with
pcDNA3.1-Ero1a were metabolically labelled for 5 min in the presence of 5 mM
DTT and then chased for 0, 3, 6 or 10 min. Cell lysates were subjected to immu-
noprecipitation with D5 and analysed on non-reducing (lanes 1–4) or reducing
(lanes 5–8) 7.5% SDS-PAGE. The Ero1a forms R, Ox1, Ox2 and the 120 kDa
complex (asterisk) are shown. Dots represent 50, 75, 100 and 150 kDa markers.
(b) Schematic to explain the mobility shift of Ero1a when analysed by reducing
SDS-PAGE. After removal of DTT, Ox2 (and Ero1a-associated complexes)
reappear and are more readily alkylated by NEM, increasing the molecular
weight (Mr). X represents putative post-translational modifications that could
also increase Ero1a molecular weight.
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have either (i) more free cysteine residues than partially
reduced Ero1a, (ii) cysteine residues that are less buried
and hence more accessible to NEM, or (iii) cysteine residues
that are subject to alternative post-translational modifications
under oxidizing conditions, such as glutathionylation at an
unpaired cysteine.7. Ero1a interactions are differentially
sensitive to oxidation cycles within the
endoplasmic reticulum
The experiment in figure 3 shows how the Ero1a intramole-
cular redox switch can counterbalance changes in the ER
redox state within minutes. Having shown that a reducing
ER could alter the monomeric and oligomeric equilibrium
of Ero1a, we investigated how Ero1a would respond when
the ER was made more oxidizing. For this, we used the
cell-permeable oxidant diamide, which can alter the redoxpotential of the cell by oxidizing glutathione [67]. Because
diamide can decrease the amount of radiolabelling when
added during the pulse, Ero1a-transfected HeLa cells were
pulsed in the presence of DTT and then chased in the pres-
ence of diamide. These conditions allowed us to follow the
fate of a synchronized Ero1a population and its response to
an oxidative flux. Ero1a and PDI were immunoprecipitated
from transfected HeLa cell lysates as before, prior to analysis
on 7.5 per cent SDS-PAGE.
Figure 4 shows the result from such an experiment. Ero1a
immunoprecipitations from mock-transfected cells were clear
of signal (figure 4a, lane 1). After a pulse without a diamide
chase, Ero1a existed as Ox1 and Ox2, a smeary 120 kDa form
and some higher molecular weight complexes that likely
include Ero1a-ERp44 (double asterisk; figure 4a, lane 2).
When the chase was supplemented with increasing concen-
trations of diamide, Ox1 disappeared at the expense of the
more compact Ox2 form (figure 4a, lanes 4–6). When Ero1a
was allowed to recover from the diamide treatment by incu-
bating the cells in normal chase medium, the protein returned
to Ox1 (figure 4a, lane 7). The upper part of the non-reducing
gels (figure 4a,c, lanes 2–7) showed that the diffuse 120 kDa
complex persisted during diamide treatment, but also
became more oxidized and compact. The complex returned
to its original status when diamide was removed (figure 4a,c,
lane 7). The reducing gel shows that in all lanes similar
amounts of Ero1a were recovered when fully reduced in
sample buffer (figure 4b, lanes 1–6). This result demonstrated
that the various oxidized forms of Ero1a were not in a simple
precursor–product relationship, but were in a dynamic equili-
brium with each other that changed according to the redox
status of the cell. Re-establishment of the status quo occurred
within 5 min of removal of the oxidant.
When PDI was immunoprecipitated from the same cell
lysates, it formed the expected approximately 120 kDa com-
plex with Ero1a when visualized under non-reducing
conditions (figure 4c, lane 2). Upon reduction, the Ero1a–
PDI complex was disrupted and monomeric Ero1a was
recovered (figure 4d, lane 2). However, when diamide was
added at 5 mM or more, the dimeric 120 kDa PDI–Ero1a
complex disappeared (figure 4c, lanes 5–6). Observation of
the reducing gels (figure 4d, lanes 5 and 6) revealed that
Ero1a could still be recovered in the PDI immunoprecipitates,
indicating that PDI and Ero1a were interacting in the higher
molecularweight disulfide-bonded complexes under these con-
ditions. The 120 kDa PDI–Ero1a complex rapidly reappeared
when diamide was washed out (figure 4c, lane 7).
The loss of the PDI–Ero1 dimer after 5 mM diamide treat-
ment correlates with the loss of Ox1, consistent with the
finding that Ox1 is the active form of Ero1a [43]. However,
Ero1a complexes persisted after 5 and 10 mM diamide treat-
ment (figure 4a, lanes 4–5, asterisk). This smear may include
Ero1a homodimers or other as yet unidentified proteins
that interact with and perhaps regulate Ero1a. The constant
Ero1a signal in the aPDI immunoprecipitation (figure 4d )
also suggests that PDI and Ero1a may be recruited to larger
complexes when the ER becomes more oxidizing.
Strikingly, Ero1a–PDI dimers and the active Ox1 form
of Ero1a are lost under oxidizing conditions when there is
less need for de novo disulfide bond formation. The PDI–
Ero1a pathway for disulfide bond formation is, therefore,
sensitive to the redox state of the ER and may recruit different
regulators during the redox cycle.
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Figure 4. The response of Ero1a to an oxidative wave. HeLa cells transfected with pcDNA3.1-Ero1a (a,c and d, lanes 2–7; b, lanes 1–6) or mock-transfected cells
(a,c and d, lane 1) were metabolically labelled in the presence of 5 mM DTT and then washed and chased for 10 min in the presence of 0, 1.2, 2.5, 5 and 10 mM
diamide (Dia). A 5 mM diamide-treated dish then was allowed to recover by washing and chasing with normal chase medium for 5 min (a,c and d, lane 7; b lane
6). Ero1a (a and b) or PDI (c and d ) were immunoprecipitated from the cell lysates and analysed on non-reducing (a,c) or reducing (b,d ) 7.5% SDS-PAGE. Ero1a R,
Ox1 and Ox2, together with the 120 kDa complex (asterisk) and an additional S–S linked complex (double asterisk) are indicated. Dots represent 50, 75, 100 and
150 kDa markers.
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in vivo
Ero1a is an unusual example of a redox-active protein
with conformation-dependent, DTT-resistant domains. Exper-
iments frommultiple laboratories, including ours, showed that
Ero1 is redox regulated (reviewed in [68]). This is reflected in
the relative distribution and dynamic response of Ero1a Ox1
(active) and Ox2 (inactive) to ER redox flux. PDI and Ero1a
participate in a buffered feedback loop that maintains disulfide
bond formation at an appropriate level when ER redox
conditions fluctuate. Strongly reducing conditions disrupt
Ero1b–PDI complexes at steady state [66,69], so it will be infor-
mative to directly compare the interactions of glycosylated
Ero1a and Ero1b with PDI. In vivo, cells will not encounter
DTTor diamide, butwill be exposed to a range of physiological
redox-active species; so howEro1a and PDI respond to reactive
oxygen species during hypoxia, nutrient flux and metabolic
stress is an important question for the future.Reduction of the Ero1 regulatory disulfides, by PDI or other
mechanisms, is necessary for its activation [68]. Similarly, the
redox-dependent Ox1–Ox2 transition from an active to an
inactive form is likely to be important in preventing hyper-
oxidation, which might be detrimental for reactions requiring
PDI-dependent isomerization or reduction of substrates.
Active Ox1 is decommissioned when required, supported by
our experiments in which Ero1 rapidly and reversibly converts
to Ox2 after diamide treatment (figure 4). The very strong
inherent redox regulatory capacity of Ero1a has been con-
firmed by RNAi knockdown experiments in which the
contributions of Ero1a, peroxiredoxin IV and vitamin K epox-
ide reductase (VKOR) to oxidative refolding of albumin were
compared side by side [70]. Knockdown of Ero1a gave the
most severe delay in recovery of oxidative protein folding,
confirming that the Ero1–PDI pathway is the primary source
of oxidizing equivalents. Whether this holds for all types of
protein clients and all physiological conditions remains to
be established.
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‘machine’ in the endoplasmic reticulum
Experiments presentedhere and in the literature show that Ero1a
interacts specifically with PDI [42] and ERp44 [51] in disulfide-
bonded complexes, and with itself as a homodimer [69]. Here,
we show that other interactions are possible under mildly
reducing conditions (figure 2). A numberof discrete proteins dis-
ulfide-linked to Ero1a appear when the redox balance is altered.
Whether these proteins are components of a larger ER-resident
machine for the control of oxidative protein folding is open to
question. One possibility is that other proteins involved in disul-
fide bond formation and regulation such as peroxiredoxin IV,
glutathione peroxidases and VKOR are brought together with
PDI andEro1a, perhaps toER subdomains in a redox-dependent
manner. In support of this idea,we note frommanyof our Ero1a
immunoprecipitation and blotting experiments that complexes
resolve towards the top of the stacking gel on non-reducing
SDS-PAGE; these complex(es) readily reformwhen normal con-
ditions are restored after redox flux (e.g. figure 3). Although it is
possible that these complexes contain misfolded Ero1a, the
expression levels of Ero1a in transfection experiments are com-
parable with endogenous levels of Eros in some tissues [29,69]
and after induction of Ero1a by the unfolded protein response
or by hypoxia [71,72]. Disulfide trapping combined with
SDS-PAGE is an excellent tool for identifying potential redox-
active partnerships, but it cannot discriminate between different
higher-order complexes that may exist under native conditions.
Some attempt has been made to probe the nature of Ero1 com-
plexes in vivo using gel filtration. For example, analysis of
Ero1b from the stomach and pancreas, where Ero1b is highly
expressed, shows that the majority of Ero1b elutes with a profile
consistent with that of a complex [69].
Otherchaperonenetworks in theERhavebeendetected,with
BiP (Grp78) a key protein hub for mediating interactions with
components of the translocation, protein folding and stress sen-
sing machineries (e.g. [73–75]). By associating with different
PDI family members, BiP can be involved in both productive
oxidative protein folding (by associatingwith PDI) and in reduc-
tive unfolding for protein degradation (by associating with
ERdJ5) [76,77]. BiP may be able to multi-task partly because of
regulation by post-translational modifications: ADP-ribosylation
of BiP has recently been shown to be important for BiP involve-
ment in the unfolded protein response [78]. However, our
understanding of the interplay between different ER chaperones
remains incomplete. As an example, Jansen et al. [79] have pro-
posed an interaction map for ER chaperones that highlights a
hitherto unappreciated role of cyclophilins in the function of
PDI proteins. Cyclophilin B can interact with at least PDI,
ERp72 and P5 and there are additional interactions between
ER-localized FK-binding proteins and ERp57, ERp29 and
ERp19. It is clear that different protein folding complexes exist
in the ER and it will be interesting to see how Ero1 proteins func-
tionally relate to these networks, particularly during times of
physiological stress or high secretory demand.10. Material and methods
(a) Cell lines
Themonocytic cell lineTHP1 (gift from J. Robinson)wasmaintained
in Roswell Park Memorial Institute medium, the fibrosarcoma
HT1080 was maintained in Dulbecco’s modified Eagle’s medium(DMEM) and the human cervical carcinoma cell line HeLa was
maintained in DMEM with non-essential amino acids. The cell
lines were supplemented with 8 per cent fetal calf serum (FCS),
100 units ml21 penicillin, 100 mg ml21 streptomycin and 2 mM
glutamax and maintained at 378C and 5 per cent CO2.
(b) Antibodies and cDNA
The polyclonal anti-PDI serumhas been described previously [42].
The polyclonal antiserum D5 was raised against non-reduced,
reduced and denatured forms of an amylose resin-purified,
mannose binding protein–Ero1a fusion protein (New England
Biolabs) expressed in Escherichia coli [79]. The monoclonal anti-
body 2G4 was raised against recombinant full-length Ero1a [59].
The construction and sequencing of the Ero1a cDNA behind the
T7 promoter in pcDNA3.1 has been previously described [9].
(c) Transfections
HeLa cells cultured in 6 cm dishes were transiently transfec-
ted with 2 mg pcDNA3.1-Ero1a mixed with 10 ml lipofectin
(Invitrogen) according to the manufacturer’s instructions.
(d) Detection of endogenous Ero1a
HeLa, HT1080 and THP1 cells were lysed in 600 ml of lysis buffer
(20 mM MES, 30 mM Tris, 100 mM NaCl, pH 7.4), with 1 per cent
Triton X-100, 10 mgml each of chymostatin, leupeptin, antipain
and pepstatin supplemented with 20 mM NEM as an alkylating
agent. Post-nuclear supernatantswere prepared by centrifugation at
16 100g for 10 min at 48C and equal amounts of protein (Bradford
assay) were loaded onto SDS-PAGE in Laemmli sample buffer
with or without 50 mM DTT as a reducing agent. Proteins were
transferred to polyvinylidene difluoride membranes for 2 h and
immunodetection was performed using 2G4 Mab tissue culture
supernatant as the primary antibody, and 1 : 3000 GAMPO (Dako)
as the secondary antibody. Proteins were visualized by enhanced
chemiluminescence (GE Healthcare) and exposure to film (Kodak).
(e) Metabolic labelling and pulse-chase analysis
Sub-confluent HeLa cells in 6 cm dishes were starved with MEM
lacking cysteine and methionine (Invitrogen) for 30 min, pulse-
labelled for the times stated with 10 mCi [35S]-labelling mix per
dish and subsequently chased when necessary with complete
medium supplemented with 5 per cent FCS, 10 mM HEPES pH
7.4, 5 mM methionine, 5 mM cysteine and 1 mM cycloheximide.
At given time intervals, the chase was stopped by flooding the
cells with ice-cold HBSS (Invitrogen) supplemented with 20 mM
NEMto trap folding intermediates. In someexperiments, freshlypre-
pared DTT or diamide (Sigma) solutions were added to the pulse or
chasemedium, as stated. The cellswere lysed in 600 ml of lysis buffer
(20 mMMES, 30 mMTris, 100 mMNaCl, pH 7.4), containing 1 per
cent Triton X-100, 10 mgml21 each of chymostatin, leupeptin, anti-
pain and pepstatin A, 1 mM PMSF, and 20 mM NEM and the
nuclei removed by centrifugation for 10 min at 48C and 16 000 g.
Immunoprecipitations were performed at 48C for either 2 h or
overnight using antibodies immobilized on 30 ml of a 10 per cent
suspension of protein A sepharose beads. Collected complexes
were washed twice at room temperature in wash buffer (300 mM
NaCl, 0.05% Triton X-100 and 0.05% SDS, 10 mM Tris-HCl, pH
8.6) prior to uptake in sample buffer. After a 3 min incubation at
958C, half the samples were reduced with 50 mM DTT, and the
proteins were analysed by 7.5 per cent SDS-PAGE.
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